Incretins (GLP-1, GIP, DPP-4) are secreted in response to meal. The GLP-1 has very shorter half-life (1–2 min), meanwhile it was degraded by DPP-4 enzyme. The present novel, Teneligliptin which has greatest receptor selectivity and has longer half-life compared to other gliptins. The promising dipp-4 inhibition which can enhance the GLP-1 concentration in the blood. Augmentation of GLP-1 levels are helpful to reduce the weight loss in obesity subjects along with reversing metabolic syndrome components. GLP-1 analogues are gold mine and are succeeded in subjects with obesity. Apart from pharmacotherapy, lifestyle modification in the form of strict diet restrictions and physical exercise are the corner stone intervention for obesity, but subjects are filed to achieve it. Furthermore, there are currently few anti-obesity drugs available, and additional safe and effective therapeutic options for the treatment of obesity are needed. Teneligliptin is developed to treat diabetes, and which do not produce hypoglycaemic effect alone. Hence, considering its safety we are aimed evaluate the non-glycemic effects in non-diabetic obese subjects. The present prospective study was registered in the Clinical trial registry of India, Regd. ID: CTRI/2020/02/023329 [Registered on: 14/02/2020].